Posted by Michael Wonder on 01 Feb 2023
Artiva Biotherapeutics receives FDA fast track designation for AB-101
31 January 2023 - Granted fast track designation by US FDA for the treatment of relapsed/refractory non-Hodgkin lymphoma of B cell origin, in combination with rituximab.
Artiva Biotherapeutics announced today that the US FDA has granted fast track designation to Artiva’s lead program AB-101.
